(MENAFN- PR Newswire) Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO, March 20, 2025 / …

Rockville, MD, March 18, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the The global rare neurological disease treatment market was valued at USD 41.8 billion in 2024 and has been forecasted to …

(MENAFN- PR Newswire) SKY-0515 is Skyhawk's investigational small molecule RNA splicing modifier developed through the company's novel RNA-splicing platform. SKY-0515 is designed to reduce both HTT protein and PMS1 protein, an additional key driver …

-  LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential wild-type HTT in a clinically relevant Huntington’s disease mouse model -  Administration of LETI-101 in nonhuman …

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 HEALEY ALS basket trial, which is trying to accelerate the search for new therapies for the devastating neurodegenerative …

Medicine scientist using computer while holding test tube with red liquid solution for research ... [+] development. Biochemistry woman with protection glasses and gloves studying lab flaskImage by DC Studio on Freepik A new discovery offers hope for …

Ottawa, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The global clinical trials market size was valued at USD 120.98 billion in 2024 and is expected to hit around USD 186.09 billion by 2034 with a CAGR of 4.4% from 2025 to 2034, a study published by Statifacts a …

A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease and triggering downstream pathologies and motor …

~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Feb. …

Breaking News Novartis to assume responsibility for PTC518's development, manufacturing and commercialization. 12.02.24 PTC Therapeutics Inc. has signed an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, …